Fabiola D'ambrosio
Endocrinology, Diabetes & Metabolism · Tallahassee, FLNPI 1720406671
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 128 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$681
- BETA Bionics, Inc.$498
- Sanofi-aventis U.S. LLC$244
- AstraZeneca$234
- Novo Nordisk$226
- Dexcom, Inc.$212
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,41299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 23 | $681 |
| BETA Bionics, Inc. | 7 | $498 |
| Sanofi-aventis U.S. LLC | 10 | $244 |
| AstraZeneca | 7 | $234 |
| Novo Nordisk | 10 | $226 |
| Dexcom, Inc. | 8 | $212 |
| Medtronic | 5 | $175 |
| AbbVie | 9 | $169 |
| Tolmar, Inc. | 4 | $156 |
| Abbott | 6 | $130 |
| Azurity Pharmaceuticals, Inc. | 6 | $110 |
| Lilly USA, LLC | 3 | $69 |
| Amgen | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 3 | $44 |
| Eton Pharmaceuticals, Inc. | 1 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $39 |
| Insulet Corporation | 2 | $38 |
| Almatica Pharma LLC | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Sequel Med Tech, LLC | 2 | $31 |
| Pfizer | 2 | $30 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Soleno Therapeutics, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Bayer | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Endo USA, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,445 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Tallahassee
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.